Who are Recombinant Flt3 Ligand's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gm-Csf, Interferon-Alpha, Gamma Interferon 1b, vemurafenib + HD IL-2, Interleukin-3, Early receiving G-CSF group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-flt3-ligand.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Recombinant Flt3 Ligand — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recombinant Flt3 Ligand (Recombinant Flt3 Ligand) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine; Hematopoietic growth factor. Area: Oncology; Immunology.

phase 3 Cytokine; Hematopoietic growth factor Flt3 receptor (FLT3) Oncology; Immunology Biologic Live · refreshed every 30 min

Target snapshot

Recombinant Flt3 Ligand (Recombinant Flt3 Ligand) — University of Southern California. Recombinant Flt3 Ligand stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells by binding to the Flt3 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Recombinant Flt3 Ligand TARGET	Recombinant Flt3 Ligand	University of Southern California	phase 3	Cytokine; Hematopoietic growth factor	Flt3 receptor (FLT3)
Gm-Csf	gm-csf	Pfizer	marketed	cytokine	GM-CSF receptor	1991-01-01
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)
Gamma Interferon 1b	Gamma Interferon 1b	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	Cytokine; Interferon	Interferon-gamma receptor (IFNGR)
vemurafenib + HD IL-2	vemurafenib + HD IL-2	Clinigen, Inc.	marketed	BRAF inhibitor + cytokine immunotherapy	BRAF V600E kinase; IL-2 receptor
Interleukin-3	Interleukin-3	Sandoz	marketed	Cytokine	IL-3 receptor (CD123)
Early receiving G-CSF group	Early receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine; Hematopoietic growth factor class)

Department of Medical Services Ministry of Public Health of Thailand · 2 drugs in this class
Hellenic Oncology Research Group · 1 drug in this class
University of Southern California · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant Flt3 Ligand — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-flt3-ligand. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab